04.30.15
Galderama has announced that it has filled two new senior leadership positions.
Kelly Huang, Ph.D. will join Galderma as Vice President and General Manager of the company's Aesthetic and Corrective Business Unit in the United States.
Chuck Paschke was named Senior Director of Organizational Health. Paschke has been with Galderma more than 18 years and most recently served as Galderma's Senior Director Leadership, Commercial Excellence.
Huang will oversee Galderma's Aesthetic and Corrective business, which includes the Restylane, Perlane, Sculptra and Dysport brands, which are sold in the U.S. and Canada.
Huang served Johnson & Johnson for 16 years, where he focused primarily on skincare as Vice President of R&D, Professional Sales & Marketing, and as a Corporate Officer of J&J's Neutrogena Corporation. More recently, he served as President of Endo Pharmaceuticals' HealthTronics division.
Todd Zavodnick, President and General Manager of Galderma Laboratories, L.P., commented,
"With the promising debut of Restylane® Silk and other launches expected in the future, it's an ideal time for someone with Kelly's wealth of experience to join Galderma's growing organization.”
Galderama’s recent launch, Restylane Silk, is the first and only FDA approved filler for lip enhancement and for the treatment of lines around the mouth in patients over the age of 21.
Huang added,"Galderma's unique vision for skin health, passionate people, and rich pipeline from a longstanding commitment to science make it a magnet in the industry. I look forward to improving patient lives by partnering with healthcare professionals to drive innovation and superior outcomes in Aesthetic medicine.”
Photos: Chuck Paschke and Kelly Huang
Kelly Huang, Ph.D. will join Galderma as Vice President and General Manager of the company's Aesthetic and Corrective Business Unit in the United States.
Chuck Paschke was named Senior Director of Organizational Health. Paschke has been with Galderma more than 18 years and most recently served as Galderma's Senior Director Leadership, Commercial Excellence.
Huang will oversee Galderma's Aesthetic and Corrective business, which includes the Restylane, Perlane, Sculptra and Dysport brands, which are sold in the U.S. and Canada.
Huang served Johnson & Johnson for 16 years, where he focused primarily on skincare as Vice President of R&D, Professional Sales & Marketing, and as a Corporate Officer of J&J's Neutrogena Corporation. More recently, he served as President of Endo Pharmaceuticals' HealthTronics division.
Todd Zavodnick, President and General Manager of Galderma Laboratories, L.P., commented,
"With the promising debut of Restylane® Silk and other launches expected in the future, it's an ideal time for someone with Kelly's wealth of experience to join Galderma's growing organization.”
Galderama’s recent launch, Restylane Silk, is the first and only FDA approved filler for lip enhancement and for the treatment of lines around the mouth in patients over the age of 21.
Huang added,"Galderma's unique vision for skin health, passionate people, and rich pipeline from a longstanding commitment to science make it a magnet in the industry. I look forward to improving patient lives by partnering with healthcare professionals to drive innovation and superior outcomes in Aesthetic medicine.”
Photos: Chuck Paschke and Kelly Huang